Insmed (INSM) Getting Somewhat Favorable News Coverage, Study Shows

News headlines about Insmed (NASDAQ:INSM) have trended somewhat positive this week, Accern reports. The research group identifies negative and positive news coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Insmed earned a coverage optimism score of 0.13 on Accern’s scale. Accern also assigned news articles about the biopharmaceutical company an impact score of 45.7400820086912 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.

Shares of Insmed (INSM) opened at 29.11 on Thursday. The company has a 50 day moving average price of $25.67 and a 200 day moving average price of $18.76. Insmed has a 1-year low of $10.21 and a 1-year high of $31.84. The stock’s market cap is $1.82 billion.

Insmed (NASDAQ:INSM) last posted its quarterly earnings results on Thursday, August 3rd. The biopharmaceutical company reported ($0.72) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.63) by ($0.09). On average, equities analysts anticipate that Insmed will post ($2.70) EPS for the current year.

Several research analysts have recently issued reports on INSM shares. Leerink Swann increased their target price on Insmed from $27.00 to $36.00 and gave the stock an “outperform” rating in a research report on Tuesday, September 5th. Stifel Nicolaus reissued a “buy” rating and issued a $43.00 target price (up previously from $27.00) on shares of Insmed in a research report on Wednesday, September 6th. Evercore ISI increased their target price on Insmed from $28.00 to $40.00 and gave the stock an “outperform” rating in a research report on Tuesday, September 5th. Zacks Investment Research raised Insmed from a “hold” rating to a “buy” rating and set a $19.00 target price for the company in a research report on Wednesday, July 5th. Finally, Robert W. Baird started coverage on Insmed in a research report on Monday, July 10th. They issued an “outperform” rating and a $23.00 target price for the company. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and six have issued a buy rating to the company. The stock presently has an average rating of “Buy” and a consensus target price of $34.50.

COPYRIGHT VIOLATION WARNING: This piece of content was first reported by Community Financial News and is the sole property of of Community Financial News. If you are reading this piece of content on another publication, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright legislation. The correct version of this piece of content can be viewed at https://www.com-unik.info/2017/10/12/insmed-insm-getting-somewhat-favorable-news-coverage-study-shows.html.

In related news, Director Melvin Md Sharoky sold 50,000 shares of the business’s stock in a transaction that occurred on Wednesday, September 6th. The shares were sold at an average price of $27.37, for a total value of $1,368,500.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Donald J. Hayden, Jr. sold 45,000 shares of the business’s stock in a transaction that occurred on Thursday, September 7th. The stock was sold at an average price of $29.67, for a total transaction of $1,335,150.00. Following the completion of the transaction, the director now directly owns 71,131 shares of the company’s stock, valued at approximately $2,110,456.77. The disclosure for this sale can be found here. Insiders own 4.03% of the company’s stock.

About Insmed

Insmed Incorporated is a biopharmaceutical company. The Company operates through development and commercialization of therapies for patients with rare diseases segment. Its lead product candidate is ARIKAYCE, or liposomal amikacin for inhalation (LAI), which is in late-stage development for adult patients with treatment refractory nontuberculous mycobacteria (NTM) lung disease caused by Mycobacterium avium complex (MAC).

Insider Buying and Selling by Quarter for Insmed (NASDAQ:INSM)

What are top analysts saying about Insmed Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Insmed Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit